We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana Partners With Atlas to Enhance Cancer Care for Seniors
Read MoreHide Full Article
Key Takeaways
HUM offered Atlas Oncology's care model to MA members in TN and MS from the beginning of 2026.
The model provides holistic cancer support with clinical care, counseling, and care coordination services.
Integrated tools and real-time support aim to reduce ER visits and align care with patient goals.
Humana Inc. (HUM - Free Report) recently unveiled a tie-up with Atlas Oncology Partners in a bid to provide enhanced cancer care, particularly for Medicare beneficiaries. Starting Jan. 1, 2026, eligible Humana Medicare Advantage (MA) members in Tennessee and Mississippi have access to the Atlas Oncology care model.
This model delivers a comprehensive suite of services designed to support patients holistically throughout their cancer treatment journey. Locally managed interdisciplinary teams work in partnership with providers to offer high-value, wrap-around services. Patients receive both on-site and virtual clinical support for cancer-adjacent conditions that often go unaddressed during treatment. The program also includes proactive care coordination, social work, and counseling services to identify and overcome barriers to care.
In addition, the model expands access to real-time clinical support, ensuring patients can schedule same-day or next-day appointments and avoid unnecessary emergency room or urgent care visits. Integrated communication tools allow oncology teams, primary care providers, and specialists to collaborate seamlessly, keeping care plans aligned with clinical needs and quality-of-life goals. Advanced supportive care services will also be available through in-person visits from skilled clinical practitioners who help clarify treatment goals.
Cancer treatment frequently involves navigating multiple healthcare providers and making numerous visits, which can be daunting for patients and caregivers alike. For seniors enrolled in Medicare, these complexities may result in overlooked needs and gaps in care. Therefore, the integrated support that the targeted Humana members will receive from doctors, nurses, patient navigators, social workers and other specialists as a result of its alliance with Atlas Oncology seems to be a time-opportune one.
Humana makes steadfast efforts to support senior care nationwide, for which it launched the CenterWell brand in 2022. Recently, CenterWell Pharmacy announced it will dispense Eli Lilly’s obesity management medications through a new employer-focused program coordinated by independent third-party administrators, thereby expanding access to obesity care.
Benefits of the Recent Move to Humana
Humana aims to improve health outcomes for its MA members suffering from cancer as a result of the recent partnership with Atlas Oncology. The beneficial nature of the Atlas Oncology care model is likely to retain existing MA customers and attract new ones to opt for Humana’s healthcare plans.
Increased plan adoption is expected to boost HUM’s MA membership base and bring higher premium revenues to the health insurer. Total MA membership came in at 5.8 million as of Sept. 30, 2025. Overall premiums advanced 9% year over year in the first nine months of 2025.
HUM’s Share Price Performance & Zacks Rank
Shares of Humana have gained 23.5% in the past six months compared with the industry’s 12.7% growth.
Regeneron Pharmaceuticals’ earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 21.81%. The Zacks Consensus Estimate for REGN’s 2026 earnings indicates a rise of 2.3%, while the same for revenues implies an improvement of 4.8% from the respective year-earlier estimates. The consensus mark for REGN’s earnings has moved 2.4% north in the past seven days.
The bottom line of BioMarin Pharmaceutical outpaced estimates in each of the trailing four quarters, the average surprise being 66.51%. The Zacks Consensus Estimate for BMRN’s 2026 earnings indicates a rise of 48.5%, while the same for revenues implies an improvement of 5.6% from the respective year-earlier estimates. The consensus mark for BMRN’s earnings has moved 0.2% north in the past seven days.
Ensign Group’s earnings surpassed estimates in each of the last four quarters, the average surprise being 2.27%. The Zacks Consensus Estimate for ENSG’s 2026 earnings indicates a rise of 9% while the consensus mark for revenues implies an improvement of 11.3% from the respective year-earlier estimates. The consensus mark for ENSG’s earnings has moved 0.3% north in the past 60 days.
Shares of Regeneron Pharmaceuticals and Ensign Group have gained 38.7% and 25.6%, respectively, in the past six months. However, BioMarin Pharmaceutical stock has dipped 0.7% in the same time frame.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana Partners With Atlas to Enhance Cancer Care for Seniors
Key Takeaways
Humana Inc. (HUM - Free Report) recently unveiled a tie-up with Atlas Oncology Partners in a bid to provide enhanced cancer care, particularly for Medicare beneficiaries. Starting Jan. 1, 2026, eligible Humana Medicare Advantage (MA) members in Tennessee and Mississippi have access to the Atlas Oncology care model.
This model delivers a comprehensive suite of services designed to support patients holistically throughout their cancer treatment journey. Locally managed interdisciplinary teams work in partnership with providers to offer high-value, wrap-around services. Patients receive both on-site and virtual clinical support for cancer-adjacent conditions that often go unaddressed during treatment. The program also includes proactive care coordination, social work, and counseling services to identify and overcome barriers to care.
In addition, the model expands access to real-time clinical support, ensuring patients can schedule same-day or next-day appointments and avoid unnecessary emergency room or urgent care visits. Integrated communication tools allow oncology teams, primary care providers, and specialists to collaborate seamlessly, keeping care plans aligned with clinical needs and quality-of-life goals. Advanced supportive care services will also be available through in-person visits from skilled clinical practitioners who help clarify treatment goals.
Cancer treatment frequently involves navigating multiple healthcare providers and making numerous visits, which can be daunting for patients and caregivers alike. For seniors enrolled in Medicare, these complexities may result in overlooked needs and gaps in care. Therefore, the integrated support that the targeted Humana members will receive from doctors, nurses, patient navigators, social workers and other specialists as a result of its alliance with Atlas Oncology seems to be a time-opportune one.
Humana makes steadfast efforts to support senior care nationwide, for which it launched the CenterWell brand in 2022. Recently, CenterWell Pharmacy announced it will dispense Eli Lilly’s obesity management medications through a new employer-focused program coordinated by independent third-party administrators, thereby expanding access to obesity care.
Benefits of the Recent Move to Humana
Humana aims to improve health outcomes for its MA members suffering from cancer as a result of the recent partnership with Atlas Oncology. The beneficial nature of the Atlas Oncology care model is likely to retain existing MA customers and attract new ones to opt for Humana’s healthcare plans.
Increased plan adoption is expected to boost HUM’s MA membership base and bring higher premium revenues to the health insurer. Total MA membership came in at 5.8 million as of Sept. 30, 2025. Overall premiums advanced 9% year over year in the first nine months of 2025.
HUM’s Share Price Performance & Zacks Rank
Shares of Humana have gained 23.5% in the past six months compared with the industry’s 12.7% growth.
Image Source: Zacks Investment Research
HUM currently has a Zacks Rank #5 (Strong Sell).
Stocks to Consider
Some better-ranked stocks in the Medical space are Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) and The Ensign Group, Inc. (ENSG - Free Report) . While Regeneron Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), BioMarin Pharmaceutical and Ensign Group carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron Pharmaceuticals’ earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 21.81%. The Zacks Consensus Estimate for REGN’s 2026 earnings indicates a rise of 2.3%, while the same for revenues implies an improvement of 4.8% from the respective year-earlier estimates. The consensus mark for REGN’s earnings has moved 2.4% north in the past seven days.
The bottom line of BioMarin Pharmaceutical outpaced estimates in each of the trailing four quarters, the average surprise being 66.51%. The Zacks Consensus Estimate for BMRN’s 2026 earnings indicates a rise of 48.5%, while the same for revenues implies an improvement of 5.6% from the respective year-earlier estimates. The consensus mark for BMRN’s earnings has moved 0.2% north in the past seven days.
Ensign Group’s earnings surpassed estimates in each of the last four quarters, the average surprise being 2.27%. The Zacks Consensus Estimate for ENSG’s 2026 earnings indicates a rise of 9% while the consensus mark for revenues implies an improvement of 11.3% from the respective year-earlier estimates. The consensus mark for ENSG’s earnings has moved 0.3% north in the past 60 days.
Shares of Regeneron Pharmaceuticals and Ensign Group have gained 38.7% and 25.6%, respectively, in the past six months. However, BioMarin Pharmaceutical stock has dipped 0.7% in the same time frame.